Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: Reasons for discordance and impact of a single training session
American Journal of Clinical Pathology · 26.08.2025 · 164 (2) · 244-256
DOI: 10.1093/ajcp/aqaf043 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 23.05.2025. Verfasst von Yun-An Tseng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Women and Infants Hospital and Warren Alpert Medical School of Brown University, Providence, RI, Uni…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immunohistochemistry, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Objective
In the DESTINY-Breast04 trial, human epidermal growth factor receptor 2 (HER2) low (HER2-L) is defined as an HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative fluorescence in situ hybridization. Limited data report poor agreement in scoring HER2-0 vs 1+. We aim to investigate the HER2 IHC concordance rate, with focus on HER2-0 vs HER2-L groups. We evaluate the impact of a single training session on concordance.
Methods
Nine breast pathologists from the same institution reviewed 60 HER2 IHC stains on breast biopsy specimens in 2 rounds of 30 cases each. An educational slide review session was provided between the 2 rounds. Interobserver Cohen κ values were computed and compared.
Results
Overall complete agreement for HER2 IHC was noted in 37 (62%) of 60 cases, with similar agreement in the first round (19/30 [63%]) and second round (18/30 [60%]). For all 60 cases, κ values ranged from .517 to .895, with 92% of κ values in substantial agreement or better range. For combined HER2-0 and HER2-L cases, κ values ranged from .298 to .826, with only 45% of κ values in substantial agreement or better range. In HER2-L only cases, 50% of the scorer pairs of κ values were 0 or less (no agreement), and only 14% of pairs showed substantial or better agreement. The educational session did not improve the κ values. Faint and heterogeneous HER2 expression, cytoplasmic blush, dislodged cells, and in situ component led to poor concordance in HER2-0 vs HER2-L.
Conclusions
Poor concordance on HER2-0 vs HER2-L and lack of improvement after a training session likely suggest ineffective HER2 IHC expression range in HER2 low spectrum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Women and Infants Hospital and Warren Alpert Medical School of Brown University, Providence, RI, United States.
- Department of Pathology, Case Western Reserve University, Cleveland, OH, United States.
ORCID-Profile: Yun-An Tseng
Zitieren
APA
Tseng, Y. A., Tamayo, S., Abada, E., Marketkar, S., Hanley, L. C., Hansen, K., Quddus, M. R., Sung, C. J., & Singh, K. (2025). Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: Reasons for discordance and impact of a single training session. American Journal of Clinical Pathology, 164(2), 244-256. https://doi.org/10.1093/ajcp/aqaf043
Vancouver
Tseng YA, Tamayo S, Abada E, Marketkar S, Hanley LC, Hansen K, et al. Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: Reasons for discordance and impact of a single training session. American Journal of Clinical Pathology. 2025;164(2):244-256. doi:10.1093/ajcp/aqaf043
BibTeX
@article{Tseng2025,
author = {Tseng, Yun-An and Tamayo, Steffanie and Abada, Evi and Marketkar, Shivali and Hanley, Linda C and Hansen, Katrine and Quddus, M Ruhul and Sung, C James and Singh, Kamaljeet},
title = {Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: Reasons for discordance and impact of a single training session},
journal = {American Journal of Clinical Pathology},
year = {2025},
volume = {164},
number = {2},
pages = {244--256},
doi = {10.1093/ajcp/aqaf043}
}
EUVIMED